ROSANNA TARRICONE

*Associate Professor at the Department of Social and Political Science, Bocconi University, Milan*

*Associate Dean at SDA Bocconi School of Management*

Email: rosanna.tarricone@unibocconi.it

Research Unique Identifier *ORCID: 0000-0002-2009-9357*

URL for website: <https://didattica.unibocconi.it/docenti/cv.php?rif=48967&cognome=TARRICONE&nome=ROSANNA>

# Short Bio

Dr Tarricone is Associate Professor at the Department of Social and Political Science at Bocconi University and Associate Dean at the Bocconi School of Management where she leads the Division of Government, Health and Non-Profit. Dr Tarricone earned her BSc in Management at Bocconi University, her MSc in Health Services Management at the University of London and her PhD in Public Health and Public Policy at the London School of Hygiene and Tropical Medicine.

With over 100 peer-reviewed publications, Rosanna Tarricone is a leading scholar in the field of health policy with a focus on health technology assessment (HTA). She combines rigorous quantitative and qualitative methods to the empirical analysis of health care systems and health care technologies, with a strong commitment to system reform. Her HTA studies provide rigorously developed estimates of the costs and clinical benefits of several health technologies and healthcare programmes.

With over ten competitive research grants awarded from international institutions such as the European Union, the Swiss Bridge Award and InHealth (USA), Rosanna’s research is characterised by being interdisciplinary, mostly carried out through large international, mainly EU-based, consortia of scholars, and major collaborative policy development initiatives that span EU policy makers.

She has taken a leadership position in numerous Italian and European policy panels and advisory boards related to technology innovation, assessment, adoption, pricing, and appropriate utilization.

# Education

**2003** PhD in Public Health and Public Policy | London School of Hygiene and Tropical Medicine, University of London, UK

**1996** MSc Health Services Management *summa cum laude* | London School of Hygiene and Tropical Medicine, University of London, UK

**1992** BSc Management (110/110) | Bocconi University, Milan, IT

# Institutional and Academic Posts

**Since 2017 Associate Dean**

Division Government, Health and Non-Profit

Bocconi University School of Management (SDA Bocconi) | Milan | IT

**2012 – 2016 Director**

CERGAS | Centre for Research on Health and Social Care Management
Bocconi University | Milan | IT

**Since 2007 Associate Professor**

Department of Social and Political Science

Bocconi University | Milan | IT

**2008 – 2012 Scientific Director**

European Health Technology Institute for Socio-Economic Research (EHTI)

Brussels | Belgium

**2008 – 2011 Director**

Master of International Healthcare Management, Economics and Policy (MIHMEP)

SDA Bocconi School of Management | Bocconi University | Milan | IT

**2002 – 2007 Co-Director**

Master of International Healthcare Management, Economics and Policy (MIHMEP)

SDA Bocconi School of Management | Bocconi University | Milan | IT

**1998 – 2011 Head of Research Unit**Health Technology Assessment (HTA) and Economic Evaluation Analysis

CERGAS | Centre for Research on Health and Social Care Management

Bocconi University | Milan | Italy

**1999 – 2001 Coordinator**

Master of International Healthcare Management, Economics and Policy (MIHMEP)

SDA Bocconi School of Management | Bocconi University | Milan | IT

**Since 1992 Researcher**

CERGAS | Centre for Research on Health and Social Care Management

Bocconi University | Milan | Italy

# Other Appointments

**Since 2023 Member of the Technical Committee of the Inter-Parliamentary Working Group on Digital Health and Digital Therapeutics**

**Since 2023 Member of the Scientific Committee of the National Observatory on Antibiotic Resistance**

**Since 2022 Member of the EU Task Force on “Harmonised Evaluation of Digital Medical Devices in the EU” and Chair of the Advisory Group**

Chaired by the French Ministry of Health and EUnetHTA (the European network of HTA Agencies) and coordinated by the European Institute for Technology (EIT) Health, the Task Force aims at harmonising assessment methods for digital health medical devices across EU Member States, whereas the Advisory Group, composed of different stakeholders, aim at providing inputs and use-cases to the Task Force

**Since 2022 Member of the National Agency for Regional Healthcare Services (AGENAS) Work Group on Telemedicine**

Nominated by the AGENAS Director, the Work Group aims at developing methods to assess telemedicine services for community care

**Since 2022 Member of the Lombardy region Teaching Committee for the training program of Directors of Healthcare Districts**

Nominated by the Education Academy of the Lombardy region healthcare service (POLIS Lombardia), the 12-member Committee has been tasked with the development of an education programme aimed at training the new role of General Director of Healthcare Districts

**2020 – 2021 Member of the 5-expert high-level committee to support the President of the Lombardy region in the assessment of the reform of the health care system**

Nominated by the President of the Lombardy region, the 5-member expert committee was tasked to assess the current regional healthcare service and to provide recommendations on how to improve the service post Covid-19 pandemic

**2018 - 2021 Chair of the Heads of the EU Health Technology Assessment Agencies**

Tasked by the EUnetHTA Secretariat, the Chair of the EU Heads of the HTA Agencies has facilitated the harmonisation of methods and processes amongst the 27 Member States in view of the new EU HTA Regulation that has been passed on January 2022

**2018 - 2020 Member of the Italian Ministry of Health Expert Panel “Healthcare 2.0”**

Nominated by the Director General of the Italian MoH, the 3-member Expert Panel was tasked to develop a predictive model to evaluate future public healthcare expenditures in view of demographic, epidemiologic and technological innovation trends. The ultimate aim was to design health policies to keep maintaining the Italian public health care service (SSN) financially sustainable

**2017 - 2020** **Member of the Publication Management Advisory Board of ISPOR (International Society of Health Economics and Outcome Research)**

Invited member by the ISPOR President, the Publications Management Advisory Board is responsible for overseeing the management of Value in Health, Value in Health Regional Issues, and Value & Outcomes Spotlight

**2016 – 2018 Member of the Board of the International Society of Health Economics and Outcomes Research (ISPOR)**

Participation to the ISPOR Board is a competitive position achieved through public votes of over 20,000 members

**2016 Invited Expert by DG Research of the European Commission to the “Research on new methods for improved health economic evaluation workshop” to advice on the preparation of new calls for the EU-Programme Horizon 2020**

**2015 - 2017 Member of the Programme Committee for the Summer School on Health Technology Assessment for Biomedical Engineers and Medical Physicists at the University of Warwick, UK**

**2015 - 2017 Member of the Course Committee and Exam Board for the MSc in Health Services Management at Trinity College Dublin, Ireland**

**2015 - 2018 Member of the Italian Ministry of Health “Tavolo Innovazione” [Innovation Table]**

Set up by the Italian Ministry of Health, the Innovation Table was tasked with developing methods and procedures for establishing an HTA programme for medical devices in Italy that formally passed in 2019

# Publications

## Peer-reviewed papers

Armeni P, Meregaglia M, Borsoi L, Callea G, Torbica A, Benazzo F and Tarricone R. Collecting Physicians’ Preferences on Medical Devices: Are We Doing It Right? Evidence from Italian Orthopedists Using 2 Different Stated Preference Methods. *Medical Decision Making,* 2023, <https://doi.org/10.1177/0272989X231201805>

Arsenault C, Lewis TP, Kapoor NR, Okiro EA, Leslie HH, Armeni P, Jarhyan P, Doubova SV, Wright KD, Aryal A, Kounnavong S, Mohan S, Odipo E, Lee HW, Shin J, Ayele W, Medina Ranilla JG, Espinoza Pajuelo L, Derseh Mebratie A, Garcia Elorrio E, Mazzoni A, Oh J, SteelFisher GK, Tarricone R, Kruk ME. Health system quality and COVID-19 vaccination: a cross-sectional analysis in 14 countries. *Lancet Global Health*, 2023. in press

Kruk ME, Kapoor NR, Lewis TP, Arsenault C, Boutsikari EC, Breda J, Carai S, Croke K, Dayalu R, Fink G, Garcia PJ, Kassa M, Mohan S, Moshabela M, Nzinga J, Oh J, Okiro EA, Prabhakaran D, SteelFisher GK, Tarricone R, Garcia-Elorrio E. Population confidence in the health system in 15 countries: results from the first round of People’s Voice Survey. *Lancet Global Health*, 2023. in press.

Kaidar-Person O, et al. Evaluating the ability of an artificial-intelligence cloud-based platform designed to provide information prior to locoregional therapy for breast cancer in improving patient’s satisfaction with therapy: The CINDERELLA trial. *PLOS ONE*, 2023 [https://doi.org/10.1371/journal.pone.0289365](https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.org%2F10.1371%2Fjournal.pone.0289365&data=05%7C01%7Crosanna.tarricone%40unibocconi.it%7C9d52382064294b48423508dba9fe82cd%7C6bf3b57a9fb447c29ada51156518f52f%7C1%7C0%7C638290682838563111%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=IJqKKETJ6uddaJS0okTSm%2Bh9Zh9uC567ek2dEI4POIM%3D&reserved=0)

Busnelli A, Ciani O, Caroselli S, Figliuzzi M, Poli M, Levi-Setti PE, Tarricone R, Capalbo A. Implementing preconception expanded carrier screening in a universal healthcare system: a model-based cost-effectiveness analysis. *Genetics in Medicine*, 2023 <https://doi.org/10.1016/j.gim.2023.100943>

Ardito V, Sarucanian L, Rognoni C, Pieri M, Scandroglio AM, Tarricone R. Impella Versus VA-ECMO for Patients with Cardiogenic Shock: Comprehensive Systematic Literature Review and Meta-Analyses. *Journal of Cardiovascular Development and Disease*, 2023 <https://doi.org/10.3390/jcdd10040158>

Tarricone R, Banks H, Ciani O, Brower W, Drummond M, Leidl R, Martelli N, Sampietro-Colom L, Taylor R. An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations. *Expert Review of Medical Devices*, 2023 <https://doi.org/10.1080/17434440.2023.2192868>

Ardito V, Golubev G, Ciani O, Tarricone R. Evaluating Barriers and Facilitators to the Uptake of mHealth Apps in Cancer Care Using the Consolidated Framework for Implementation Research: Scoping Literature Review. *JMIR Cancer*, 2023 <https://dx.doi.org/10.2196/preprints.42092>

Bertolaccini L. Fornaro G, Ciani O, Prisciandaro E, Crisci R, Tarricone R, Spaggiari L. The Impact of Surgical Experience in VATS Lobectomy on Conversion and Patient Quality of Life: Results from a Comprehensive National Video-Assisted Thoracic Surgical Database. *Cancer*, 2023 <https://doi.org/10.3390/cancers15020410>

Torbica A, Tarricone R, Schreyögg, Drummond M. Pushing the boundaries of evaluation, diffusion, and use of medical devices in Europe: Insights from the COMED project. *Health Economics*, 2022 <https://doi.org/10.1002/hec.4600>

Ferrara L, Otto M, Aapro M, Albreht T, Jonsson B, Oberst S, Oliver K, Pisani E, Presti P, Rubio IT, Terkola R, Tarricone R. How to improve efficiency in cancer care: Dimensions, methods, and areas of evaluation. *Journal of Cancer Policy*, 2022 <https://doi.org/10.1016/j.jcpo.2022.100355>

Tarricone R, Petracca F, Cucciniello, Ciani O. Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps. *Health Economics,* 2022 <https://doi.org/10.1002/hec.4505>

Drummond M, Tarricone R, Torbica A. European Union regulation of health technology assessment: what is required for it to succeed? *The European Journal of Health Economics,* 2022 <https://doi.org/10.1007/s10198-022-01458-6>.

Borsoi L, Callea G, Tarricone R. How to Reduce Inequity of Access to Cardiac Rehabilitation After Surgical Aortic Valve Replacement. Recommendations for the Post–COVID-19 Era from a Real-World, Population-Based Study. *Clinical Therapeutics,* 2022; <https://doi.org/10.1016/j.clinthera.2022.02.002>

Meregaglia M, Tarricone R. Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms. *Pharmacoeconomics Open,* 2022 <https://doi.org/10.1007/s41669-022-00326-6>

Callea G, Federici C, Freddi R, Tarricone R. Recommendations for the design and implementation of an Early Feasibility Studies program for medical devices in the European Union. *Expert Review of Medical Devices* 2022 <https://doi.org/10.1080/17434440.2022.2075729>

Petracca F, Tempre R, Cucciniello M, Ciani O, Pompeo E, Sannino L, Lovato V, Castaman G, Ghirardini A, Tarricone R. An Electronic Patient-Reported Outcome Mobile App for Data Collection in Type a Hemophilia: Design and Usability Study. *JMIR Form Res* 2021 <https://doi.org/10.2196/25071>

Tarricone R, Robinson J. Harmonization of Health Technology Assessment Across the European Union: Lessons For The United States. *Health Affairs Blog*, 2021 <https://www.healthaffairs.org/do/10.1377/forefront.20211130.24462>

Martin B, Cereda E, Caccialanza R, Pedrazzoli P, Tarricone R, Ciani O. Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy. *Cost Effectiveness and Resource Allocation*, 2021 <https://doi.org/10.1186/s12962-021-00291-7>

Ricciardi W, Tarricone R. The evolution of the Italian National Health Service. *The Lancet*, 2021 [https://doi.org/10.1016/S0140-6736(21)01733-5](https://doi.org/10.1016/S0140-6736%2821%2901733-5)

Cucciniello, M., Petracca, F., Ciani, Tarricone R. Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials. *NPJ Digital Medicine*, 2021 <https://doi.org/10.1038/s41746-021-00517-1>

Daubner-Bendes R, Kovacs S, Niewada M, Huic H, Drummond M, Ciani O, Blankart CR, Mandrik O, Torbica A, Yfantopoulos J, Petrova G, Holownia-Voloskova M, Taylor R, Al M, Piniazhko O, Lorenzovici L, Tarricone R, Zemplényi A, Kalò Z. Quo Vadis HTA for medical devices in Central and Eastern Europe? Recommendations to address methodological challenges. *Frontiers in Public Health*, 2021 <https://doi.org/10.3389/fpubh.2020.612410>

Tarricone R, Listorti E, Tozzi V, Torbica A, Banks H, Ghislandi S, Altini M, Annicchiarico M, Ardizzoni A, Bordon P, Bossi P, Cascinu S, Numico G, Puglisi F, Fasola G. Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy. *Journal of Cancer Policy*, 2021 <https://doi.org/10.1016/j.jcpo.2021.100297>

Tarricone R, Amatucci F, Armeni P, Banks H, Borsoi L, Callea G, Ciani O, Costa F, Federici C, Torbica A, Marletta M. Establishing a national HTA program for medical devices in Italy: Overhauling a fragmented system to ensure value and equal access to new medical technologies. *Health Policy*, 2021 <https://doi.org/10.1016/j.healthpol.2021.03.003>

Pongiglione B, Torbica A, Blommestein H, de Groot S, Ciani O, Walker S, Dams F, Blankart R, Mollenkamp M, Kovács S, Tarricone R, Drummond M. Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal. *International Journal of Technology Assessment in Health Care,* 2021 <https://doi.org/10.1017/S026646232100030>

Rognoni C, Lugli M, Maleti O, Tarricone R. Clinical guidelines versus current clinical practice for the management of deep vein thrombosis. *Journal of Vascular Survey: Venous and Lymphatic Disorders*, 2021 <https://doi.org/10.1016/j.jvsv.2021.01.020>

Tarricone R, Petracca F, Ciani O, Cucciniello M. Distinguishing features in the assessment of mHealth apps. *Expert Review of Pharmacoeconomics and Outcomes Research*, 2021 https://doi:10.1080/14737167.2021.1891883

Torbica A, Rognoni C, Tarricone R. Investigating Patients’ Preferences to Inform Drug Development Decisions: Novel Insights from a Discrete Choice Experiment in Migraine. *Int. J. Environ. Res. Public Health*, 2021 <https://doi.org/10.3390/ijerph18094916>

Rognoni C, Tozzi M, Tarricone R. Endovascular versus surgical creation of arteriovenous fistula in hemodialysis patients: Cost-effectiveness and budget impact analyses. *The Journal of Vascular Access*, 2021 [https://doi.org/10.1177%2F1129729820921021](https://doi.org/10.1177/1129729820921021)

Tarricone R, Rognoni C. What can health systems learn from COVID-19? *Eur Heart J Suppl*, 2020 <https://doi.org/10.1093/eurheartj/suaa185>

Tarricone R, Ciani O, Torbica A, Brouwer W, Chaloutsos G, Drummond M, Martelli N, Persson U, Leidl R, Levin L, Sampietro-Colom L & Taylor RS. Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective. *Expert Review of Medical Devices*, 2020 <https://doi.org/10.1080/17434440.2020.1825074>

Petracca F, Ciani O, Cucciniello M, Tarricone R. Harnessing digital health technologies during and after the COVID-19 pandemic: context matters. *Journal of Medical Internet Research*, 2020 <https://doi.org/10.2196/21815>

Tarricone R, Ciani O, D’Acunto S, Scalzo S. The rise of rules: Will the new EU regulation of medical devices make us safer? *European Journal of Internal Medicine*, 2020 <https://doi.org/10.1016/j.ejim.2020.07.012>

Barchiesi M, Bulgheroni M, Federici C, Casella F, Medico MD, Torzillo D, Popescu Janu V, Tarricone R, Cogliati C. Impact of point of care ultrasound on the number of diagnostic examinations in elderly patients

<https://doi.org/10.1016/j.ejim.2020.06.026>

Rognoni, C., Cuccurullo, D., Borsoi, L. et al. Tarricone R & M Piccoli. Clinical outcomes and quality of life associated with the use of a biosynthetic mesh for complex ventral hernia repair: analysis of the “Italian Hernia Club” registry. *Scientific Reports*, 2020 <https://doi.org/10.1038/s41598-020-67821-w>

Tarricone R, Rognoni C, Arnoldo L, Mazzacane S, Caselli E. A Probiotic-Based Sanitation System for the Reduction of Healthcare Associated Infections and Antimicrobial Resistances: A Budget Impact Analysis. *Pathogens* 2020 <https://doi.org/10.3390/pathogens9060502>

Rognoni C, Lugli M, Maleti O, Tarricone R. Venous stenting for patients with outflow obstruction and leg ulcers: cost-effectiveness and budget impact analyses. *Journal of Comparative Effectiveness Research*, 2020 <https://doi.org/10.2217/cer-2020-0030>

Drummond M, Torbica A, Tarricone R. Should health technology assessment be more patient centric? If so, how? *The European Journal of Health Economics*, 2020 <https://doi.org/10.1007/s10198-020-01182-z>

Rognoni C, Armeni P, Tarricone R, Donin G. Cost–benefit Analysis in Health Care: The Case of Bariatric Surgery Compared with Diet. *Clinical Therapeutics*, 2020 <https://doi.org/10.1016/j.clinthera.2019.12.001>

Torbica A, Fornaro G, Tarricone R, Drummond M. Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis. *Value in Health,* 2020 <https://doi.org/10.1016/j.jval.2019.11.001>

Boscolo PR, Callea G, Ciani O, Tarricone R. Measuring Value in Health Care: A Comparative Analysis of Value-based Frameworks. *Clinical Therapeutics,* 2020 <https://doi.org/10.1016/j.clinthera.2019.11.017>

Tarricone R, Cucciniello M, Armeni P, Petracca P, Desouza K, Hall LK, Keefe D. Mobile Health Divide Between Clinicians and Patients in Cancer Care: Results from a Cross-Sectional International Survey. *JMIR*

Meregaglia M, Borsoi L, Cairns J, Tarricone R. Mapping health-related quality of life scores from FACT-G, FAACT and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer-cachexia. *The European Journal of Health Economics*, 2019 <https://doi.org/10.1007/s10198-017-0930-6>

Ciani C, Cucciniello M, Petracca F, Apolone G, Merlini G, Novello S, Pedrazzoli P, Zilembo N, Broglia C, Capelletto E, Garassino M, Nicod E, Tarricone R. The Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. *BMJ Open*, 2019 <http://dx.doi.org/10.1136/bmjopen-2018-025483>

Caselli E, Arnoldo L, Rognoni C, D’Accolti M, Soffritti I, Lanzoni L, Bisi M, Volta A, Tarricone R, Brusaferro S, Mazzacane S. Impact of a probiotic-based hospital sanitation on antimicrobial resistance and HAI-associated antimicrobial consumption and costs: a multicenter study. *Infectious and Drug Resistance*, 2019 [https://dx.doi.org/10.2147%2FIDR.S194670](https://dx.doi.org/10.2147/IDR.S194670)

Caselli E, Brusaferro S, Coccagna M, Arnoldo L, Berloco F, Antonioli P, Tarricone R, Pelissero G, Nola S, La Fauci V, Conte A, Tognon L, Villone G, Trua N, Mazzacane S, for the SAN-ICA Study Group. Reducing healthcare-associated infections incidence by a probiotic-based sanitation system: A multicentre, prospective, intervention study. *PLoS ONE*, 2018 <https://doi.org/10.1371/journal.pone.0199616>

Rognoni C, Ciani O, Sommariva S, Bargellini I, Bhoori S, Cioni R, Facciorusso A, Golfieri R, Gramenzi A, Mazzaferro V, Mosconi C, Ponziani F, Sacco R, Trevisani F, Tarricone R. Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. *BMC Cancer*, 2018 <https://doi.org/10.1186/s12885-018-4636-7>

Rognoni C, Andrea Bassi U, Cataldo M, Crovella C, Crovella F, Cuccurullo D, Cudemo M, De Nicola E, De Paolis P, Maria Greco V, Marioni A, Pessione S, Piccoli M, Rosignoli A, Sagnelli C, Silvestro R, Tarricone R, Trapani V, Soliani G. Budget impact analysis of a biosynthetic mesh for incisional hernia repair. *Clinical Therapeutics*, 2018 <https://doi.org/10.1016/j.clinthera.2018.09.003>

Federici C, Perego F, Borsoi L, Crosta V, Zanichelli A, Zidaro A, Tarricone R, Cicardi M. Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients. *BMJ Open,* 2018 <http://dx.doi.org/10.1136/bmjopen-2018-022291>

Pallari E, Lewison G, Ciani O, Tarricone R, Sommariva S, Begum M, and Sullivan R. The impacts of diabetes research from 31 European Countries in 2002 to 2013. *Research Evaluation*, 2018 <https://doi.org/10.1093/reseval/rvy006>

Torbica A, Tarricone R, Drummond M. Does the approach to economic evaluation in health care depend on culture, values and institutional context? *The European Journal of Health Economics*, 2018 <https://doi.org/10.1007/s10198-017-0943-1>

Rognoni C, Ciani O, Sommariva S, Tarricone R. Cost-effectiveness analysis of treatments involving radioembolization in intermediate stage hepatocellular carcinoma. *Journal of Comparative Effectiveness Research*, 2018 <https://doi.org/10.2217/cer-2017-0050>

Rognoni C, Tarricone R. Intermittent catheterisation with hydrophilic and non-hydrophilic urinary catheters: systematic literature review and meta-analyses. *BMC Urology*, 2017 <https://doi.org/10.1186/s12894-016-0191-1>

Berger ML, Sox H, Willke RJ, Brixner DL, Eichler H-G, Goettsch W, Madigan D, Makady A, Schneeweiss S, Tarricone R, Wang SV, Watkins J, Mullins CD. Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making. *Value in Health*, 2017 <https://doi.org/10.1016/j.jval.2017.08.3019>

Begum M, Lewison G, Sommariva S, Ciani O, Tarricone R, and Sullivan R. European Diabetes Research and Its Funding, 2002-13. *Diabetic Medicine*, 2017 <https://doi.org/10.1111/dme.13411>

Mujica-Mota R, Watson LK, Tarricone R, Jäger M. Cost-Effectiveness of Timely Versus Delayed Primary Total Hip Replacement In Germany: A Social Health Insurance Perspective. *Orthopedic Reviews*, 2017 [https://dx.doi.org/10.4081%2For.2017.7161](https://dx.doi.org/10.4081/or.2017.7161)

Callea G, Cavallo MC, Tarricone R, Torbica A. Learning effect and diffusion of innovative medical devices: the case of transcatheter aortic valve implantation in Italy. *Journal of Comparative Effectiveness Research*, 2017 <https://doi.org/10.2217/cer-2016-0083>

Cervigni M, Sommariva M, Tenaglia R, Porru D, Ostardo D, Giammò A, Trevisan S, Frangione V, Ciani O, Tarricone R, Pappagallo GL. A randomized, open‐label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. *Neurourology and Urodynamics*, 2017 <https://doi.org/10.1002/nau.23091>

Rognoni C, Sommariva S, Ciani O, Tarricone R. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. *Value in Health*, 2017 <https://doi.org/10.1016/j.jval.2016.09.2397>

Rothery C, Claxton K, Palmera S, Epstein D, Tarricone R, Sculpher M. Characterising uncertainty in the assessment of medical devices and determining future research needs. *Health Economics*, 2017 <https://doi.org/10.1002/hec.3467>

Tarricone R, Torbica A, Drummond M. Challenges in the Assessment of Medical Devices: the MedtecHTA project. *Health Economics*, 2017 <https://doi.org/10.1002/hec.3469>

Tarricone R, Torbica A, Drummond M. (for the MedtecHTA project group) Key Recommendations from the MedtecHTA Project. *Health Economics*, 2017 <https://doi.org/10.1002/hec.3468>

Tarricone R, Callea G, Ogorevc M, Prevolnik Rupel V. Improving the methods for the economic evaluation of medical devices. *Health Economics*, 2017 <https://doi.org/10.1002/hec.3471>

Callea A, Armeni P, Marsilio M, Jommi C, Tarricone R. The impact of HTA and procurement practices on the selection and prices of medical devices. *Social Science and Medicine*, 2017 <https://doi.org/10.1016/j.socscimed.2016.11.038>

Rognoni C & Tarricone R. Healthcare Resource Consumption for Intermittent Catheterization: Cost-Effectiveness of Hydrophilic Catheters and Budget Impact Analyses. *BMJ Open* 2017 <http://dx.doi.org/10.1136/bmjopen-2016-012360>

Drummond M, Tarricone R, Torbica A. Incentivising research into the effectiveness of medical devices. *The European Journal of Health Economics*, 2016 <https://doi.org/10.1007/s10198-016-0820-3>

Rognoni C, Ciani O, Sommariva S, Facciorusso A, Tarricone R, Bhoori S, Mazzaferro V. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. *Oncotarget*, 2016 [https://dx.doi.org/10.18632%2Foncotarget.11644](https://dx.doi.org/10.18632/oncotarget.11644)

Tarricone R, Boscolo P.R, Armeni P. What type of clinical evidence is needed to assess health technologies? *European Respiratory Review* 2016;25:259-265 10.1183/16000617.0016-2016

Armeni P, Boscolo PR, Tarricone R, Capodanno D, Maggioni A, Grasso C, Maisano F. Real-World Cost Effectiveness of Mitraclip combined with Medical Therapy Versus Medical Therapy Alone in Patients with Moderate or Severe Mitral Regurgitation. *International Journal of Cardiology*, 2016 <https://doi.org/10.1016/j.ijcard.2016.01.212>

Ciani O, Arendsen E, Romancik M, Lunik R, Costantini E, Di Biase M, Morgia G, Fragalà E, Roman T, Bernat M, Guazzoni G, Tarricone R, Lazzeri M. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) for the treatment of female recurrent urinary tract infections: a European multicenter nested case-control study. *BMJ Open*, 2016 <http://dx.doi.org/10.1136/bmjopen-2015-009669>

Tarricone R, Medina Lara A, Abu Koush D. A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life. *Critical Reviews in Oncology/Hematology*, 2016 <https://doi.org/10.1016/j.critrevonc.2015.12.012>

Tarricone R, Ricca G, Nyanzi-Wakholi B, Medina Lara A. Impact of cancer anorexia-Cachexia Syndrome on Health-Related Quality of Life and Resource Utilisation: a Systematic Review. *Critical Reviews in Oncology/Hematology*, 2016 <https://doi.org/10.1016/j.critrevonc.2015.12.008>

Rognoni C, Venturini S, Meregaglia M, Marmifero M, Tarricone R. Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. *Clinical Drug Investigation*, 2016 <https://doi.org/10.1007/s40261-015-0361-z>

Sommariva S, Pongiglione B, Tarricone R. Impact of Chemotherapy- Induced Nausea and Vomiting on Health-Related Quality of Life and Resource Utilization: a Systematic Review. *Critical Reviews in Oncology/Hematology*, 2016 <https://doi.org/10.1016/j.critrevonc.2015.12.001>

Ciani O, Armeni P, Boscolo PR, Cavazza M, Jommi C, Tarricone R. De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making. *Health Policy & Technology*, 2016 <https://doi.org/10.1016/j.hlpt.2015.10.005>

Valzania C, Torbica A, Tarricone R, Leyva F, Boriani G. Implant rates of cardiac implantable electrical devices in Europe: a systematic literature review. *Health Policy*, 2016 <https://doi.org/10.1016/j.healthpol.2015.11.001>

Sommariva S, Tarricone R, Lazzeri M, Ricciardi W, Montorsi F. Prognostic value of CCP score in patients with prostate cancer: a systematic review and meta-analysis. *European Urology*, 2016 <https://doi.org/10.1016/j.eururo.2014.11.038>

Gonzales FM, Finch AP, Armeni P, Boscolo PR, Tarricone R. Comparative Effectiveness of Mitraclip versus Optimal Medical Therapy in High-Risk Surgical Patients: a Comprehensive Review. *Expert Review of Medical Devices*, 2015 <https://doi.org/10.1586/17434440.2015.1054807>

Generali D, Venturini S, Rognoni C, Ciani R, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A Network Meta-Analysis of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer. *Breast Cancer Research and Treatment*, 2015 <https://doi.org/10.1007/s10549-015-3453-9>

Gehring M, Jommi C, Tarricone R, Cirenei M, Ambrosio G. Towards a More Competitive Italy in Clinical Research: The Survey of Attitudes towards Trial sites in Europe (The SAT-EU StudyTM). *Epidemiology, Biostatistics and Public Health* 2015;12(1):1-9. doi: 10.2427/10246

Beresniak A, Medina-Lara A, Auraye JP, Weverf A, Praetf JC, Tarricone R, Torbica A, Dupont D, Lamure M, Durue G. Validation of the underlining assumptions of the QALY outcome: results from the ECHOUTCOME European project. *Pharmacoeconomics*, 2015 <https://doi.org/10.1007/s40273-014-0216-0>

Tarricone R, Torbica A, Ferrè F, Drummond M. Generating Appropriate Clinical Data for Value Assessment of Medical Devices: What Role Does Regulation Play? *Expert Review of Pharmacoeconomics and Outcome Research*, 2014 <https://doi.org/10.1586/14737167.2014.950233>

Compagni A, Melegaro A, Tarricone R. Genetic Screening for the Predisposition to Venous Thromboembolism: A Cost-Utility Analysis of Clinical Practice in the Italian HealthCare System. *Value in Health*, 2013 <https://doi.org/10.1016/j.jval.2013.05.003>

Tarricone R. Setting the Scene: The Challenges of Universal Health Coverage and the Contribution of Management Education. *Value in Health* 2013 <https://doi.org/10.1016/j.jval.2012.10.009>

Calciolari S, Torbica A, Tarricone R. Explaining the health costs associated with managing intracranial aneurysms in Italy. *Applied Health Economics and Health Policy*, 2013 <https://doi.org/10.1007/s40258-013-0041-1>

Ciani O, Grassi D, Tarricone R. An economic perspective on urinary tract infection: the "costs of resignation". *Clinical Drug Investigation,* 2013 <https://doi.org/10.1007/s40261-013-0069-x>

Salvatore C, Boscolo PR, Tarricone R. Planning and control of medical device investments by Italian public health authorities: A means to improve the decision-making process. *Journal of Medical Marketing*, 2013 [https://doi.org/10.1177%2F1745790413498410](https://doi.org/10.1177/1745790413498410)

Drummond M, Tarricone R, Torbica A. Assessing the added value of health technologies: reconciling different perspectives. *Value in Health*, 2013 <https://doi.org/10.1016/j.jval.2012.10.007>

Smith BD, Tarricone R, Vella V. The role of product life cycle in medical technology innovation. *Journal of Medical Marketing*, 2013 [https://doi.org/10.1177%2F1745790413476876](https://doi.org/10.1177/1745790413476876)

Callea G, Tarricone R, Mujica Mota R. The economic impact of a medical device company’s location in Italy. *Journal of Medical Marketing*, 2013 [https://doi.org/10.1177%2F1745790412468930](https://doi.org/10.1177/1745790412468930)

Mujica-Mota R, Tarricone R, Ciani O, Bridges JFP, Drummond M. Determinants of demand for total hip and and knee arthroplasty: a systematic literature review. *BMC Health Services Research*, 2012 <https://doi.org/10.1186/1472-6963-12-225>

Ciani O, Tarricone R, Torbica A. Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems? *Health Policy*, 2012 <https://doi.org/10.1016/j.healthpol.2012.09.017>

Callea G, Tarricone R, Medina Lara A. Economic evidence of interventions for acute myocardial infarction: a review of the literature. *Eurointervention*, 2012 <https://doi.org/10.4244/eijv8spa12>

Tarricone R, Drummond M. Challenges in the clinical and economic evaluation of medical devices: the case of transcathether aortic valve implantation. *Journal of Medical Marketing*, 2011 [https://doi.org/10.1177%2F1745790411412242](https://doi.org/10.1177/1745790411412242)

Sorenson C, Tarricone R, Siebert M, Drummond M. Applying Health Economics for Policy Decision Making: Do Devices Differ From Drugs? *Europace*, 2011 <https://doi.org/10.1093/europace/eur089>

Tarricone R, Torbica A, Franzetti F, Rosenthal VD. Hospital cost of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of Intensive Care Units in Italy. *Cost Effectiveness and Resource Allocation*, 2010 <https://doi.org/10.1186/1478-7547-8-8>

Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. *Urology*, 2010 <https://doi.org/10.1016/j.urology.2009.07.1325>

Drummond M, Griffin A, Tarricone R. Economic Evaluation for Devices: Same or Different? *Value in Health*, 2009;12(4):402-404

Tarricone R, Aguzzi G, Musì F, Fariselli L, Casasco A. Cost-effectiveness for trigeminal neuralgia: Cyberknife vs microvascular decompression. *Neuropsychiatric Disease and Treatment*, 2008 [https://dx.doi.org/10.2147%2Fndt.s2827](https://dx.doi.org/10.2147/ndt.s2827)

Tarricone R, Aguzzi G, Capone A, Caravaggi CM, Esposito S, Franzetti F, Muzzi A, Ricci L, Bassetti M. How complicated skin and soft tissue infections are treated in Italy: economic evaluation of inpatient intravenous antibiotic treatment in seven hospitals. *Journal of Medical Economics*, 2008 <https://doi.org/10.3111/13696990802113196>

Tarricone R. Cost-of-Illness analysis – What room in health economics? *Health Policy*, 2006 <https://doi.org/10.1016/j.healthpol.2005.07.016>

Roggero P, Tarricone R, Mangiaterra V, Vicoli M. What do people think about disabled youth and employment in developed and developing countries? Results from an e-discussion hosted by the World Bank. *Disability and Society*, 2006 <https://doi.org/10.1080/09687590600918370>

Tarricone R, Girolami F. Economic Evaluation of a New Antiemetic Drug – Palonosteron versus Ondansetron. Assessment of the Drug Price Ratio in Five European countries. *Clinical Drug Investigation*, 2005 <https://doi.org/10.2165/00044011-200525090-00005>

Gerzeli S, Tarricone R, Zolo P, Colangelo I, Busca MR, Gandolfo C. The Economic Burden of Stroke in Italy. The EcLIPSE Study: Economic Longitudinal Incidence-based Project for Stroke Evaluation. *Neurological Science*, 2005 <https://doi.org/10.1007/s10072-005-0439-0>

Tarricone R, Marchetti M, Lamotte M, Annemans L, de Jong P. What reimbursement for coronary revascularization with drug-eluting stents? *The European Journal of Health Economics*, 2004 <https://doi.org/10.1007/s10198-004-0258-x>

Heller B, Tarricone R. Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. *Current Medical Research and Opinion*, 2004 <https://doi.org/10.1185/030079904125004411>

Gillette JA, Tarricone R. Economic Evaluation of osteoarthritis treatment in Europe. *Expert Opinion on Pharmacotherapy*, 2003 <https://doi.org/10.1517/14656566.4.3.327>

Tarricone R, Martelli E, Parazzini F, Darbà J, Le Pen C, Rovira J. Economic Evaluation of Nimesulide Versus Diclofenac in the Treatment of Osteoarthritis in France, Italy and Spain. *Clinical Drug Investigation*, 2001 <https://doi.org/10.2165/00044011-200121070-00001>

Tarricone R, Fattore G, Gerzeli S, Serra G, Taddei C, Percudani M. The costs of pharmacological treatment for major depression. The Italian prospective multi-centre observational incidence-based study. *Pharmacoeconomics*, 2000 <https://doi.org/10.2165/00019053-200017020-00005>

Tarricone R, Gerzeli S, Montanelli R, Frattura L, Percudani M, Racagni G. Direct and indirect costs of Schizophrenia in community psychiatric services in Italy. The GISIES study. *Health Policy*, 2000 [https://doi.org/10.1016/S0168-8510(99)00078-0](https://doi.org/10.1016/S0168-8510%2899%2900078-0)

## Peer-reviewed Books and Chapters

Ciani O, Torbica A, Tarricone R. (2021) Core Outcome Set in Surgical Oncology: Why, What and How to Measure. In: Montorsi M. (eds) Volume-Outcome Relationship in Oncological Surgery. Updates in Surgery. Springer, Cham. <https://doi.org/10.1007/978-3-030-51806-6_2>

Tarricone R, Torbica A. Basic Principles of Health Technology Assessment, Economic Evaluation, and Costing of Healthcare Programs. In Abdominal Wall Surgery, Springer, Cham (ed) 2019; pp 141-156.

Cavallo MC, Callea G, Tarricone R. State-of-the-Art of Abdominal Wall Surgery in Italy: Coding, Reimbursement, Hospitalisations and Expenditure for Surgical Meshes. In Abdominal Wall Surgery, Springer, Cham (ed) 2019; pp 87-104.

Drummond M, Tarricone R, Torbica A. Economic Evaluation of Medical Devices. In Oxford Research Encyclopedia of Economics and Finance edited by J Hamilton, A Dixit, S Edwards, and K Judd, Oxford University Press, 2018; doi:10.1093/acrefore/9780190625979.013.105.

Drummond M, Tarricone R. Public Versus Private Financing. In The Myths of Healthcare. Adinolfi P, Borgonovi E (eds). Springer 2018; pp:134-137.

Taylor R, Ciani O, Tarricone R. Comparing Drug and Non-Drug Technologies in Comparative Effectiveness Research. In: Comparative effectiveness research, Ed. Adrian Levy, Vol. 1, Handbook of health services research, edited by B. Sobolev. New York: Springer Science + Business Media, 2015.

Tarricone R, Torbica A. Costing and performance in healthcare management. Faltin, F.W, Kenett, R.S., Ruggeri, F. (edited by) Statistical methods in healthcare. Wiley, UK, 2012, pp.386-404.

Tarricone R, Tsouros A. Homecare in Europe. The Solid Facts, WHO Regional Office for Europe, 2008.

# Awarded Competitive Grants

**PI**  **HORIZON JU IHI (two stage)**

HEU-EFS | Harmonised Approach to Early Feasibility Studies For Medical Devices In The European Union.

**Aim**: to develop a novel innovative and harmonized framework for EFS in the EU, as one integrated step of the evidence generation cycle.

**Euros** 10.56 million

**Time** 2023 - 2027

**WP Leader EU4Health programme**

JACARDI | Joint Action on CARdiovascular diseases and Diabetes

**Aim**: to reduce the burden of cardiovascular disease (CVD) and diabetes (DM) in EU countries, both at individual and societal level. JACARDI is designed to integrate validated best practices and/or (cost-)effective interventions across countries and regions through transnational pilot initiatives, complementing and reinforcing existing policies and programs.

**Euro**: 66.0 million

**Time**: 2023-2027

**Scientific**

**Supervisor HORIZON Europe Framework Programme (single-stage)**

HI-PRIX **|** Health Innovation Next Generation Payment & Pricing Models. Balancing Sustainability of Innovation with Sustainability of Healthcare.

**Aim**: to formulate new pricing and payment schemes that can be used across technology classes, therapeutic areas, setting and healthcare systems/geographies together with a related set of principles that may guide successful adjustment and flexible implementation to the particular context of use.

**Euros** 5.5 million

**Grant No** 101095593

**Time** 2023 - 2025

**WP Leader** **HORIZON Europe Framework Programme (single-stage)**

CINDERELLA | Clinical Validation of an AI-based approach to improve the shared decision-making process and outcomes in Breast Cancer Patients proposed for Locoregional treatment.

**Aim**: to develop a prospective randomized clinical trial to evaluate the CINDERELLA APProach vs. the standard conventional approach with respect to patient’s expectations, aesthetic outcome, satisfaction, quality of life, feasibility and cost-effectiveness.

**Euros** 5.4 million

**Grant No**.101057389

**Time** 2022 - 2026

**Scientific**

**Supervisor/**

**WP Leader HORIZON 2020 - Research and Innovation Framework Programme (single-stage)**

COMED | Pushing the boundaries of costs and outcomes analysis of medical technologies.

**Aim**: to developing new approaches to assess health technologies within the paradigms of Health Technology Assessment and Health System Performance

**Euros** 3.02 million

**Grant No.** 779306

**Time** 2018 – 2021

**Main scientific outputs:** Tarricone et al. (2022) Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps | [*Health Economics*](https://onlinelibrary.wiley.com/doi/full/10.1002/hec.4505); Cucciniello, M et al. & Tarricone R. (2021) Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials [| *Nature Digital Medicine*](https://www.nature.com/articles/s41746-021-00517-1)*;* Tarricone et al. (2021) Distinguishing features in the assessment of mHealth apps | [*Expert Review of Pharmacoeconomics and Outcomes Research*](https://www.tandfonline.com/doi/full/10.1080/14737167.2021.1891883)

**PI Italian Ministry of Health research program (single-stage)**

Healthcare 2.0 | Public health care predictive model

**Aim**: to estimate the impact of technological innovation in cancer on public health care expenditure.

**Euros** 180,000

**Grant No.** CIG 7390436CB5

**Time** 2019 – 2020

**Main scientific output:** Tarricone et al. (2021) Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy | [*Journal of Cancer Policy*](https://www.sciencedirect.com/science/article/pii/S221353832100028X)

**PI Italian Ministry of Health research program (single-stage)**

Medical devices market surveillance

**Aims**: to measure the impact of the new EU Regulation of medical devices on public institutions and manufacturers, to develop methods to estimate the costs for the Italian healthcare system of medical devices recalls, and to improve methods for the lifelong assessment of medical devices

**Euros** 2.445 million

**Time** 2018 – 2021

**Grant No.** CUP J46C18000670005

**Main scientific output:** Tarricone et al. (2020) The rise of rules: Will the new EU regulation of medical devices make us safer? | [*European Journal of Internal Medicine*](https://www.ejinme.com/article/S0953-6205%2820%2930295-8/fulltext)

**WP Leader HORIZON 2020 - Research and Innovation Framework Programme (single-stage)**

IMPACT HTA | Improved methods and actionable tools for enhancing Health Technology Assessment

**Aim**: to investigate the determinants of major differences in costs and outcomes among EU Member States as to healthcare services

**Euros** 4.59 million

**Time** 2018 - 2020

**Grant No.** 779312

**WP Leader** **EU Seventh Framework Programme (two-stage)**

MAPPING NCDs | Mapping Chronic Non-Communicable Diseases Research Activities and their Impact.

**Aim**: to map EU member state activity, investment and initiatives to combat NCDs, describing and quantifying their impact in five key disease areas: cardiovascular disease, chronic respiratory diseases, diabetes, cancer and mental health

**Euros** 1.997 million

**Time** 2013 -2015

**Grant No.** 602536

**Main scientific output:** Pallari et al. (2018) The impacts of diabetes research from 31 European Countries in 2002 to 2013 | [*Research Evaluation*](https://academic.oup.com/rev/article-abstract/27/3/270/4969899)

**Co-PI Swiss Bridge Award | Switzerland (two-stage)**

Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer

**Aim**: to measure, compare and assess costs and outcomes of two different follow-ups for informing policy decisions on the most cost-effective strategy

**Euros** 100,000

**Time** 2013 - ongoing

**PI EU Seventh Framework Programme (two-stages)**

MEDTECHTA | Methods for Health Technology Assessment of Medical Devices: A European Perspective

**Aim**: to develop methods to assess medical devices

**Euros** 2.055 million

**Time** 2012 – 2015

**Main scientific outputs:** Tarricone et al (2017) Challenges in the Assessment of Medical Devices: the MedtecHTA project | [*Health Economics*](https://onlinelibrary.wiley.com/doi/full/10.1002/hec.3469); Tarricone et al. (2017) Key Recommendations from the MedtecHTA Project | [*Health Economics*](https://onlinelibrary.wiley.com/doi/full/10.1002/hec.3468); Tarricone et al. (2017) Improving the methods for the economic evaluation of medical devices | [*Health Economics*](https://onlinelibrary.wiley.com/doi/full/10.1002/hec.3471)

**Partner EU Lifelong Learning Programme “Leonardo Da Vinci” (one-stage)**

Health Governance through Europe.

Aim: to acquire best practises in health governance across EU countries

**Euros** 44,000

**Time** 2011

**WP Leader Italian Ministry of Health research program (one-stage)**

The economic impact of genetic tests on the Italian NHS: identification of clinical pathways, cost-effectiveness and cost-utility analysis and assessment of health policies in Europe

Aim: to investigate the economic implications of the adoption and diffusion of genetic tests in several disease areas

**Euros** 380,000

**Time** 2011 - 2012

**Main scientific output:** Compagni A, Melegaro A, Tarricone R. (2013) Genetic Screening for the Predisposition to Venous Thromboembolism: A Cost-Utility Analysis of Clinical Practice in the Italian HealthCare System | [*Value in Health*](https://www.sciencedirect.com/science/article/pii/S1098301513018196)

**Coordinator InHealth | USA (one-stage)**

The effect of medical devices on health and retirement

**Aim**: to estimate the effect that hip replacement therapy is likely to have on delaying the retirement age of patients with musculoskeletal conditions

**USD** 240,000

**Time** 2010 – 2012

**Main scientific outputs**: Mujica-Mota R, Tarricone R, et al. (2012) Determinants of demand for total hip and knee arthroplasty: a systematic literature review | [*BMC Health Services Research*](https://link.springer.com/article/10.1186/1472-6963-12-225); Mujica-Mota R, Watson LK, Tarricone R, et al. (2017) Cost-Effectiveness of Timely Versus Delayed Primary Total Hip Replacement In Germany: A Social Health Insurance Perspective | [*Orthopedic Reviews*](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641833/)

**Co-PI Italian Ministry of Health research program (two-stage)**

Cost-utility of conventional haemodialysis vs. short daily haemodialysis for patients coming from automated peritoneal dialysis: a randomised controlled trial

**Aim:** to assess costs and health outcomes of patients treated by two different haemodialysis strategies

**Euros** 300,000

**Time** 2010 - 2013

**WP Leader EU Seventh Framework Programme (two-stage)**

ECHOUTCOME | European Consortium in Healthcare Outcomes and Cost-Benefit research

**Aim:** to compare the health system organizations of the 27 Member States and studying the robustness of health outcomes currently used by health technology assessment authorities in Europe

**Euros** 1.064 million

**Time** 2009 – 2012

**Grant No.** 242203

**Main scientific output:** Beresniak et al. (2015) Validation of the underlining assumptions of the QALY outcome: results from the ECHOUTCOME European project | [*Pharmacoeconomics*](https://link.springer.com/article/10.1007/s40273-014-0216-0)

**WP Leader Italian Ministry of Research and University | PRIN (one-stage)**

Health Technology Assessment of genetic screening: cost-utility analysis of the genetic screening for the predisposition to venous thromboembolism

**Aim**: to assess costs and outcomes of genetic screening with a focus on the predisposition to venous thromboembolism in order to advice policy-makers as to the diffusion of genetic screening tests in current medical practice

**Euros** 109,000

**Time** 2007 – 2009

**Main scientific output:** Compagni A, Melegaro A, Tarricone R (2012) Systematic review of the economic literature on genetic testing for the prevention of venous thromboembolism | [*Italian Journal of Public Health*](https://www.researchgate.net/profile/Alessandro-Cocchella/publication/250002805_Health_technology_assessment_of_genetic_testing_for_susceptibility_to_venous_thromboembolism_in_Italy_-_Chapter_52_Genetic_testing_for_inherited_thrombophilia_the_patients%27_perspective/links/55b3311508ae9289a0859418/Health-technology-assessment-of-genetic-testing-for-susceptibility-to-venous-thromboembolism-in-Italy-Chapter-52-Genetic-testing-for-inherited-thrombophilia-the-patients-perspective.pdf)

# (a selection of) Presentations at national and international conferences

*Incorporation of New Technologies in Health Care in SUS and in Supplementary Health Care. How to enhance and advance?* Global Forum | Fronteiras da Saude, Brasil | 26 October 2023

*Key Challenges in Assessing High-Risk Medical* Devices *|* International Society of Health Economics and Outcomes Research (ISPOR) South Africa Chapter Virtual Conference Nov 2022

*Independent Scientific Opinion for CE mark or early dialogue for HTA: a unique expert panel for both?* IssuePanel | International Society of Health Economics and Outcomes Research (ISPOR) Virtual Dec 2nd 2021

*Clinical Evidence Generation across the Lifecycle of High Risk Implantable Medical Devices*. Issue Panel | ISPOR Europe Nov 16th 2020

*Regulation and HTA of Medical Devices in EU: What Can We Learn?* Issue Panel | ISPOR Tokyo (Japan) Sept 8th-13th 2018

*Assessment of medical devices: key features and major challenges* Workshop | ISPOR Tokyo (Japan) Sept 8th-13th 2018

*Has the time come to replace randomized controlled trials with real-world data: a case of medical devices?* Issue Panel | Annual General Conference of ISPOR, 21st-23rd, Baltimore (USA), 2018

*mHealth among clinicians and patients in cancer care: How to address the digital divide?*" Issue Panel | XX Annual Conference of ISPOR, 6th – 8th, Glasgow (UK), 2017

*HTA Methods for Medical Technologies: Development, Applications, and Future Advancements* | HTAi Annual Meeting, Rome, 19th – 21st June

*HTA of Medical Devices: Are We Getting Closer to Solve the Puzzle?* | HTAi Annual Meeting, Rome, 19th – 21st June

*Use of Real-world Evidence to Shape Health Policies for Medical Devices |* ISPOR, 22nd Annual International Meeting, Boston (USA), 22nd – 24th May 2017.

*Incentivizing Research into the Effectiveness of Medical Devices* | ISPOR 19th Annual European Congress, Vienna, 9th October – 2nd November 2016.

*New Challenges for High-Risk Medical Devices in Europe. How to Achieve the Balance Between The Demand For Early Product Launch And Safety?* | ISPOR 19th Annual European Congress, Vienna, 9th October – 2nd November 2016.

*The digital divide between clinicians and patients. Results from an international e-survey on mHealth in cancer supportive care* | MASCC Annual Meeting on Supportive Care in Cancer, Adelaide, Australia, June 23th – 25th, 2016.

*Regulation and Market Access for Medical Devices* | XIV Mediterranean Conference on Medical and Biological Engineering and Computing, Paphos, Cyprus, March 31st – April 2nd, 2016.

*HTA of drugs and medical devices: same or different?* | XIV Mediterranean Conference on Medical and Biological Engineering and Computing, Paphos, Cyprus, March 31st – April 2nd, 2016.

*Advancing methods of Health Technology Assessment for medical devices: key recommendations from the EU MedTecHTA project* | International Health Economics Association, 11th World Congress, Milan, Italy, 12th-15th July, 2015.

*Retrospective analysis of Ialuril vs. Standard of Care in Recurrent Urinary Tract Infections: RAISC-RUTI study protocol and preliminary results* (with Ciani O and Lazzeri M) | 29th Annual EAU Congress, Stockholm, Sweden, 12th April 2014.

*Does assessing the value for money of medical devices require a flexible approach?* | ISPOR Dublin, UK, 4th-6th November, 2013.

*Health Technology Assessment: Opportunities and Limitations* | European Health Policy Forum (EHF) Gastein, Austria, 1st-3rd October, 2013.

*Do HTA practices and procurement policies impact expenditures for medical devices?* (with Armeni P, Boscolo PR, Callea G, Cavazza M, Ciani O, Jommi C, Marsilio M, Torbica A) | EHMA Milan, Italy, 26th-28th June, 2013.

*A Real-World Cost-Effectiveness Analysis of the Genetic Screening for Predisposition to Venous Thromboembolism (VTE) in the Italian Context* (with Compagni A, Melegaro A, Villari P, Di Maria E, Ricciardi G) | International Congress on Health Economics, Toronto, Canada, 9th-13th July, 2011.

*Treatment Innovations for Osteoarthritis: a budget impact analysis of chondroitin sulphate and NSAIDs* | EULAR (European League against Rheumatism). Copenhagen, Denmark, 11th June, 2009.

*How to improve user access to innovative medical devices: what is needed?* | 5th Annual HTAi Meeting, Montreal, Canada, 6th-9th July, 2008.

*Are Medical Devices more challenging to evaluate than Drugs?* | 10th ISPOR European Conference, Dublin, Ireland, 20th-23rd October, 2007.

*Employment and Youth with Disability: sharing knowledge and practice* (with Roggero R) | Employment and Disability, World Bank, Washington DC, 30th-1st December, 2004.

*Cost-Effectiveness Analysis of Cypher* (with Marchetti M) | 2nd International Congress on Clinical and Interventional Cardiology, Taormina, Italy, 25th-29th May, 2002.

*Direct costs of stroke in Italy* (with Colangelo I, Gerzeli S, Busca R) | International Health Economics Association Conference, York, UK, 21st-26th July, 2001.

*Direct costs of Schizophrenia* (with Gerzeli S, Montanelli R) | 3rd International Congress on Health Economics, Evora, Portugal, 15th-17th October, 1997.

*The economic burden of Major Depression* (with Fattore G) | International Health Economics Association Inaugural Conference, Vancouver, Canada, 19th-23rd May, 1996.

*A comparative study on costs incurred in delivering endoscopy services to patients with IBD and those with other gastroenteric pathologies* (with De Benedetti A) | VRQ Conference, Venice, 26th May 1994.

# Invited lectures

**2019 Key characteristics of health and healthcare** @University of Florida, Gainesville, USA

**2019 Health Economic Assessment of Medical Devices: Challenges and Solutions** @Health Economic and Policy Analysis Centre | National University of Ireland, Galway, Ireland

**2016 The Italian Healthcare system** @Health Policy and Management | School of Medicine | Trinity College, Dublin, Ireland

**2015 Economic Evaluation Analysis of Healthcare Programmes** @Summer School on Health Technology Assessment for Biomedical Engineers and Medical Physicists | University of Warwick, UK

**2015** **Advancing methods of Health Technology Assessment for medical devices: an introduction to the EU MedTecHTA project** @Haute Authorité de Santé | Paris, France

**2014** **Cost-of-Illness Analysis** @ISPOR Israel Chapter | Tel Aviv, Israel

**1998 – 2005** **Cost Management in Health Care** @School of Statistics in Health Care | University of Pavia, Italy

**2004** **Economic Evaluation and Clinical Governance** @ Faculty of Medicine | University La Cattolica, Rome

**1997 – 1999** **Decision Analysis in Health Care** @Faculty of Pharmacology | La Sapienza University, Rome, Italy

**1997 Health Care Management** @Institute of Health Care | University of Malta, Malta

**1996** **Economic Evaluation in the Healthcare Sector: an aid to decision-makers?** @University of Kuopio, Finland

# Reviewing Activities

Reviewer for (selected) *Applied Health Economics and Health Policy, BMJ Open, Critical Reviews in Oncology/Hematology, Expert Review of Medical Devices, Expert Review of Pharmacoeconomics and Outcome Research, European Journal of Health Economics, Health Policy, Health Affairs, International Journal of Technology Assessment in Health Care, Pharmacoeconomics, Social Science and Medicine, Value in Health*

Review panel member for scientific grants: Swiss National Research Council, Medical Research Council (UK), European Commission Horizon 2020, Emilia-Romagna, Italy (Research Grants for Clinical Governance)

# Memberships of Scientific Societies

**AIES** | Italian Association of Health Economics

**EHMA** | European Health Management Association

**iHEA** | international Health Economics Association

**ISPOR** | International Society of Health Economics and Outcome Research

**HTAi** | international Health Technology Assessment Association